US OptionsDetailed Quotes
VKTX250411P25000
- 3.73
- 0.000.00%
15min DelayTrading Apr 11 16:00 ET
0.00High0.00Low
0.00Open3.73Pre Close0 Volume19 Open Interest25.00Strike Price0.00Turnover7122.98%IV8.04%PremiumApr 11, 2025Expiry Date1.87Intrinsic Value100Multiplier-4DDays to Expiry1.86Extrinsic Value100Contract SizeAmericanOptions Type-0.8839Delta0.0927Gamma6.20Leverage Ratio-313.1905Theta0.0000Rho-5.48Eff Leverage0.0001Vega
Viking Therapeutics Stock Discussion
Sign in to post a comment
$Viking Therapeutics (VKTX.US)$
Could the failure of Pfizer's obesity pill force the drugmaker to spend billions on an acquisition to break into the blockbuster weight-loss market wide open???? VKTX becomes more appealing now but who says HIMS doesnt swoop in before Pfizer does??? $Hims & Hers Health (HIMS.US)$
following closely in the next 1 to 3 months VKTX will advance as more data is set to release from trials and their stock returns to 40-50 with a buyout in the 120 - 150 ra...
Could the failure of Pfizer's obesity pill force the drugmaker to spend billions on an acquisition to break into the blockbuster weight-loss market wide open???? VKTX becomes more appealing now but who says HIMS doesnt swoop in before Pfizer does??? $Hims & Hers Health (HIMS.US)$
following closely in the next 1 to 3 months VKTX will advance as more data is set to release from trials and their stock returns to 40-50 with a buyout in the 120 - 150 ra...
3
2
1
$Viking Therapeutics (VKTX.US)$
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Viking Therapeutics (NASDAQ: VKTX) has completed enrollment in its Phase 2 VENTURE-Oral Dosing Trial of VK2735, a dual GLP-1 and GIP receptor agonist tablet for obesity treatment. The 13-week study enrolled 280 adults with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with weight-related conditions.
The trial's primary endpoint foc...
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Viking Therapeutics (NASDAQ: VKTX) has completed enrollment in its Phase 2 VENTURE-Oral Dosing Trial of VK2735, a dual GLP-1 and GIP receptor agonist tablet for obesity treatment. The 13-week study enrolled 280 adults with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with weight-related conditions.
The trial's primary endpoint foc...
2
1
$Viking Therapeutics (VKTX.US)$
Major Milestone: Viking's Oral Weight Loss Drug Advances with 280-Patient Phase 2 Trial
Major Milestone: Viking's Oral Weight Loss Drug Advances with 280-Patient Phase 2 Trial
1
1
2
Here are the levels to watch on VKTX today. Under 27.02 decent open space on the way down to the 24.83.
$Viking Therapeutics (VKTX.US)$
$Viking Therapeutics (VKTX.US)$
1
$Viking Therapeutics (VKTX.US)$
Viking Therapeutics Locks Massive GLP-1 Supply Deal: Game-Changing Partnership Covers Both Oral and Injectable Forms
Viking Therapeutics Locks Massive GLP-1 Supply Deal: Game-Changing Partnership Covers Both Oral and Injectable Forms
1
No comment yet
Tonyco : Maybe, but they won't want to use debt for it right now...
74529537 : It seems that being acquired is very promising!
